Skip to main content
NEW IDENTITY. SAME PURPOSE. Janssen is now J&J Innovative Medicine.  
 
VISIT JANSSEN GLOBAL
 
 
 

UK
change location▼

Search
Search

Welcome to Janssen UK

Visit Janssen Global

Media Centre

The News Centre is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree Cancel

Press Releases

06, November, 2024

MHRA grants marketing authorisation for BALVERSA®▼ (erdafitinib) as monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC) harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting

29, October, 2024

TREMFYA® (Guselkumab) is the first IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn’s disease

17, October, 2024

Johnson & Johnson transitions Remicade® (infliximab) and Simponi® (golimumab) for treatment of patients with Inflammatory Diseases

10, October, 2024

NICE lifts restriction and recommends bispecific antibody TECVAYLI®▼ (teclistamab) for all eligible patients with relapsed and refractory multiple myeloma after three treatments

14, September, 2024

RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

12, September, 2024

RYBREVANT®▼ (amivantamab) plus lazertinib shows favourable overall survival trend in EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib

View more Press Releases

Quick Links

 

FOLLOW US

 

Twitter

Follow us on Twitter